The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer with driver or non-driver gene alterations: a retrospective cohort study

Key Points

• High PD-L1 expression correlates with better survival in advanced NSCLC patients, particularly among different gene alteration groups.
• In KRAS mutant individuals, the presence of KRAS G12C or TP53 co-mutations is associated with improved survival outcomes.
• The analysis employed a retrospective cohort design to evaluate the efficacy of first-line immune checkpoint inhibitors across various subgroups.
• Findings suggest the importance of PD-L1 as a predictive biomarker in guiding treatment decisions for advanced NSCLC.

Abstract